Evaluating SPRC-AB01 in Post-Surgical Subjects With Chronic Sinusitis
NCT ID: NCT00447837
Last Updated: 2008-03-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
180 participants
INTERVENTIONAL
2006-10-31
2008-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Dose-finding Study to Assess the Efficacy, Safety and Tolerability of Tobramycin Inhalation Powder in Patients With Non-Cystic Fibrosis Bronchiectasis and Pulmonary P. Aeruginosa Infection
NCT02712983
Tobramycin Delivered by Nebulized Sonic Aerosol for Chronic Rhinosinusitis Treatment of Cystic Fibrosis Patients
NCT02888730
Tobramycin Inhalation Solution for Pseudomonas Aeruginosa Eradication in Bronchiectasis
NCT06093191
Tobramycin in Bronchiectasis Colonized With Pseudmonas Aeruginosa
NCT03715322
A Study of the Clinical Benefit of Tobramycin Inhalation Solution
NCT06106789
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
SPRC-AB01
90 mg/3 mL BID, 180 mg/3 mL bid, placebo
2
SPRC-AB01
90 mg/3 mL BID, 180 mg/3 mL bid, placebo
3
SPRC-AB01
90 mg/3 mL BID, 180 mg/3 mL bid, placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SPRC-AB01
90 mg/3 mL BID, 180 mg/3 mL bid, placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* A documented history of chronic sinusitis with clinical signs and symptoms suggestive of inflammation or infection for at least 90 consecutive days.
* A documented history of sinus surgery \> 90 days.
* Nasal endoscopic exam documenting purulence (pus) from an open sinus cavity with mucosal swelling/edema.
* Women of childbearing potential must have a negative serum pregnancy test and must use adequate birth control throughout the study.
Exclusion Criteria
* Use of any investigational drug/device within 30 days of study screening.
* The following medications will require a certain washout period as determined by the protocol: systemic corticosteroids, mast cells and/or leukotriene inhibitors, anti-inflammatories, decongestants, antihistamines, non-steroidal anti-inflammatory (NSAID) or cyclooxygenase (COX)-2 inhibitors, antibiotics or antifungals.
* Presence of other infections which may require use of systemic antibiotics.
* Known allergy or hypersensitivity to aminoglycosides or other study drug formulation components.
* Recent hospitalization for any reason and/or major surgeries within 30 days of study screening.
* Major elective and/or nasal and/or sinus surgical procedures (including sinuplasty) within 90 days before or 90 days after study screening.
* Known history of neurological or muscular disorders.
* Diagnosis of an immunodeficiency disease.
* Previous diagnosis of cystic fibrosis, ciliary dyskinesias, Kartagener syndrome, empty nose syndrome, Wegener granulomatosis, Churg-Strauss syndrome, Samter syndrome, or sarcoidosis.
* Current or known history of tinnitus, vertigo, or significant sensorineural hearing loss.
* Recent history of alcohol or drug abuse.
* Inability to understand the nature, scope, and possible consequences of the study or study procedures, unless cared for by a legally authorized representative.
* Inability to adhere to the study requirements.
* Previous participation in any Naryx Pharma protocol.
16 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Naryx Pharma
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Naryx Pharma
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinical Research Consultants
Hoover, Alabama, United States
NEA Clinic
Jonesboro, Arkansas, United States
Central California Clinical Research
Fresno, California, United States
Allergy Research Foundation, Inc
Los Angeles, California, United States
Children's Hospital of Orange County
Orange, California, United States
Allergy Medical Group of the North Area Inc
Roseville, California, United States
Sacramento Ear, Nose & Throat
Sacramento, California, United States
Allergy & Asthma Medical Group and Research Center
San Diego, California, United States
1st Allergy & Clinical Research Center
Centennial, Colorado, United States
Colorado Otolaryngology Associates
Colorado Springs, Colorado, United States
The Connecticut Sinus Center
Bridgeport, Connecticut, United States
Clinical Trials Management LLC
Boca Raton, Florida, United States
Allergy & Asthma Center / South Florida ENT
Fort Lauderdale, Florida, United States
Clinical Research of West Florida
Tampa, Florida, United States
Nasal Sinus and Allergy Institute
Alpharetta, Georgia, United States
Northeast Georgia Research Center
Gainsville, Georgia, United States
Northside Ear, Nose & Throat
Roswell, Georgia, United States
Commonwealth Ear, Nose & Throat
Louisville, Kentucky, United States
Calvert Internal Medicine Group
Prince Frederick, Maryland, United States
Massachusetts General Hospital - Allergy Clinical Research
Boston, Massachusetts, United States
Henry Ford Health System
Detroit, Michigan, United States
Clinical Research Institute
Plymouth, Minnesota, United States
Allergy & Sinus Center
Greenwood, Mississippi, United States
Clinical Research Group of Montana
Bozeman, Montana, United States
Shah Eye Ear Nose & Throat
Lawrenceville, New Jersey, United States
ENT Care
Somerville, New Jersey, United States
Weill Medical College-Department of Otorhinolaryngology
New York, New York, United States
University of Rochester-Otolaryngology Associates
Rochester, New York, United States
Center for Allergy and Asthma of Bronx and Westchester
The Bronx, New York, United States
Charlotte Eye, Ear, Nose & Throat Associates
Charlotte, North Carolina, United States
Wilmington Health Associates
Wilmington, North Carolina, United States
Cleveland Clinic - Head & Neck Institute
Cleveland, Ohio, United States
Toledo Center for Clinical Research
Sylvania, Ohio, United States
University of Pittsburgh - The Eye and Ear Institute
Pittsburgh, Pennsylvania, United States
ADAC Research PA
Greenville, South Carolina, United States
The Jackson Clinic
Jackson, Tennessee, United States
The Allergy, Asthma & Sinus Center
Knoxville, Tennessee, United States
Ear, Nose & Throat Associates of Corpus Christi / Research
Corpus Christi, Texas, United States
Allergy and Asthma Associates
Houston, Texas, United States
Research Across America
Plano, Texas, United States
San Antonio Ear, Nose and Throat Research
San Antonio, Texas, United States
Marshfield Clinic
Marshfield, Wisconsin, United States
Marshfield Clinic - Weston Center
Weston, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SPRC-AB01-003
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.